Financials LIDDS AB

Equities

LIDDS

SE0001958612

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 06:18:28 2024-04-30 am EDT 5-day change 1st Jan Change
0.17 SEK +4.29% Intraday chart for LIDDS AB +6.25% +57.41%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 312.6 349.2 372 437.6 324.6 58.92
Enterprise Value (EV) 1 297.3 323.1 364.4 401.5 290.6 57.65
P/E ratio -46.9 x -90.5 x -15.4 x -12.3 x -8.2 x -1.58 x
Yield - - - - - -
Capitalization / Revenue 304 x 45 x - 1,268 x 91.3 x 31.2 x
EV / Revenue 289 x 41.7 x - 1,164 x 81.8 x 30.5 x
EV / EBITDA - -292,159,575 x -28,077,641 x -12,611,686 x -7,895,438 x -1,595,580 x
EV / FCF -13.3 x -13.9 x -12.6 x -20.9 x -9.34 x -2.55 x
FCF Yield -7.5% -7.19% -7.93% -4.78% -10.7% -39.2%
Price to Book 2.46 x 2.2 x 2.5 x 10.2 x 6.69 x 3.84 x
Nbr of stocks (in thousands) 20,981 23,051 23,692 29,667 33,990 34,740
Reference price 2 14.90 15.15 15.70 14.75 9.550 1.696
Announcement Date 4/25/18 4/25/19 4/22/20 4/16/21 4/26/22 4/25/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 1.029 7.755 - 0.345 3.554 1.888
EBITDA - -1.106 -12.98 -31.84 -36.81 -36.13
EBIT 1 -6.668 -2.683 -18.99 -31.97 -37.15 -36.62
Operating Margin -648.34% -34.6% - -9,265.8% -1,045.33% -1,939.51%
Earnings before Tax (EBT) 1 -6.669 -3.748 -23.83 -32.33 -37.27 -36.86
Net income 1 -6.669 -3.748 -23.83 -32.33 -37.27 -36.86
Net margin -648.44% -48.33% - -9,372.17% -1,048.68% -1,952.33%
EPS 2 -0.3179 -0.1674 -1.017 -1.203 -1.164 -1.072
Free Cash Flow 1 -22.29 -23.24 -28.89 -19.17 -31.11 -22.63
FCF margin -2,167.47% -299.68% - -5,557.79% -875.42% -1,198.41%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/25/18 4/25/19 4/22/20 4/16/21 4/26/22 4/25/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 15.3 26.1 7.56 36.1 34 1.26
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -22.3 -23.2 -28.9 -19.2 -31.1 -22.6
ROE (net income / shareholders' equity) -5.56% -2.62% -15.3% -111% -81.6% -115%
ROA (Net income/ Total Assets) -3.31% -1.14% -7.38% -52.8% -42.3% -56.2%
Assets 1 201.5 328.8 322.7 61.24 88.11 65.63
Book Value Per Share 2 6.070 6.880 6.270 1.440 1.430 0.4400
Cash Flow per Share 2 0.7300 1.130 0.3100 1.220 1.000 0.1500
Capex - - 0.29 0.61 0.74 0.05
Capex / Sales - - - 177.97% 20.71% 2.75%
Announcement Date 4/25/18 4/25/19 4/22/20 4/16/21 4/26/22 4/25/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise